Deferiprone - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic drug sources for deferiprone and what is the scope of patent protection?
Deferiprone
is the generic ingredient in two branded drugs marketed by Chiesi, Hikma, and Taro Pharm Inds Ltd, and is included in five NDAs. There are six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Deferiprone has forty-three patent family members in twenty-seven countries.
There are four drug master file entries for deferiprone. Four suppliers are listed for this compound.
Summary for deferiprone
International Patents: | 43 |
US Patents: | 6 |
Tradenames: | 2 |
Applicants: | 3 |
NDAs: | 5 |
Drug Master File Entries: | 4 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 122 |
Clinical Trials: | 62 |
Patent Applications: | 3,444 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price trends for deferiprone |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for deferiprone |
What excipients (inactive ingredients) are in deferiprone? | deferiprone excipients list |
DailyMed Link: | deferiprone at DailyMed |
Recent Clinical Trials for deferiprone
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Assiut University | Phase 1 |
Rohan Dharmakumar | Phase 1 |
Lipomed AG | Phase 1 |
Pharmacology for deferiprone
Drug Class | Iron Chelator |
Mechanism of Action | Iron Chelating Activity |
Anatomical Therapeutic Chemical (ATC) Classes for deferiprone
Paragraph IV (Patent) Challenges for DEFERIPRONE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
FERRIPROX | Tablets | deferiprone | 500 mg | 021825 | 1 | 2016-01-29 |
US Patents and Regulatory Information for deferiprone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chiesi | FERRIPROX | deferiprone | TABLET;ORAL | 212269-001 | May 19, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Chiesi | FERRIPROX | deferiprone | SOLUTION;ORAL | 208030-001 | Sep 9, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Chiesi | FERRIPROX | deferiprone | SOLUTION;ORAL | 208030-002 | Apr 20, 2018 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Chiesi | FERRIPROX | deferiprone | TABLET;ORAL | 021825-002 | Jul 25, 2019 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Hikma | DEFERIPRONE | deferiprone | TABLET;ORAL | 213239-002 | Feb 8, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Chiesi | FERRIPROX | deferiprone | SOLUTION;ORAL | 208030-001 | Sep 9, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Hikma | DEFERIPRONE | deferiprone | TABLET;ORAL | 213239-001 | Mar 29, 2021 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for deferiprone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Chiesi | FERRIPROX | deferiprone | SOLUTION;ORAL | 208030-001 | Sep 9, 2015 | ⤷ Try a Trial | ⤷ Try a Trial |
Chiesi | FERRIPROX | deferiprone | SOLUTION;ORAL | 208030-002 | Apr 20, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
Chiesi | FERRIPROX | deferiprone | TABLET;ORAL | 212269-001 | May 19, 2020 | ⤷ Try a Trial | ⤷ Try a Trial |
Chiesi | FERRIPROX | deferiprone | TABLET;ORAL | 021825-001 | Oct 14, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
Chiesi | FERRIPROX | deferiprone | TABLET;ORAL | 021825-002 | Jul 25, 2019 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for deferiprone
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Chiesi Farmaceutici S.p.A. | Ferriprox | deferiprone | EMEA/H/C/000236 Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction. |
Authorised | no | no | no | 1999-08-25 | |
Lipomed GmbH | Deferiprone Lipomed | deferiprone | EMEA/H/C/004710 Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Deferiprone Lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction. |
Authorised | yes | no | no | 2018-09-19 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for deferiprone
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Portugal | 2268282 | ⤷ Try a Trial | |
Mexico | 2020004107 | TABLETAS DE DEFERIPRONA DE LIBERACION RETRASADA Y METODOS DE USO DE LAS MISMAS. (DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAME.) | ⤷ Try a Trial |
European Patent Office | 3684344 | COMPRIMÉS DE DÉFÉRIPRONE À LIBÉRATION RETARDÉE ET PROCÉDÉS D'UTILISATION CORRESPONDANTS (DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAME) | ⤷ Try a Trial |
Australia | 2008355464 | Liquid formulation for deferiprone with palatable taste | ⤷ Try a Trial |
Canada | 3077514 | COMPRIMES DE DEFERIPRONE A LIBERATION RETARDEE ET PROCEDES D'UTILISATION CORRESPONDANTS (DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAME) | ⤷ Try a Trial |
Ukraine | 102254 | ЖИДКИЙ СОСТАВ ДЛЯ ДЕФЕРИПРОНА С ПРИЯТНЫМ ВКУСОМ;РІДКИЙ СКЛАД ДЛЯ ДЕФЕРИПРОНУ З ПРИЄМНИМ СМАКОМ (Normal;heading 1;heading 2;heading 3;LIQUID FORMULATION FOR DEFERIPRONE WITH PALATABLE TASTE) | ⤷ Try a Trial |
Australia | 2018357350 | Delayed release deferiprone tablets and methods of using the same | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.